Data Supplement from Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations

Autor: Jean-Charles Soria, Valerie Meresse, Ernesto Guarin, Michel Paques, Wilfried Ernst Erich Eberhardt, Jean J.L. Tessier, Françoise Kraeber-Bodéré, Miro Venturi, Simon Pacey, James Larkin, Luiz Paz-Ares, Emiliano Calvo, Mark R. Middleton, Jean-Philippe Spano, Jan H.M. Schellens, Veronique Dieras, Maria Martinez-Garcia, Fabrice Barlesi, Lisa Zimmer
Rok vydání: 2023
DOI: 10.1158/1078-0432.22454862.v1
Popis: Supplementary Figure 2. Case study: 64-year old female with BRAF V600-mutant melanoma (A) Immunhistochemistry for Ki67 expression showing a reduction between baseline and cycle1/day15 in lymph node biopsies (B) Immunhistochemistry for pERK expression showing a reduction between baseline and cycle5/day1 in lymph node biopsies (C) FDG-PET uptake at baseline (D) FDG-PET metabolic partial response at day 15 of cycle 1 (E) CT scan images at baseline (F) CT scan images at day 1 of cycle 5 show a 80% reduction in target lesion size, indicating partial response
Databáze: OpenAIRE